Obstructive sleep apnoea increases lipolysis and deteriorates glucose homeostasis in patients with type 2 diabetes mellitus
Minh Duc Trinh, Andrea Plíhalová, Jan Gojda, Kateřina Westlake, Jan Špička, Zuzana Lattová, Martin Pretl, J. Polák
Abstract
Abstract Obstructive sleep apnoea (OSA) is associated with type 2 diabetes mellitus (T2DM). However, mechanisms mediating association between these two conditions remain unclear. This study investigated, whether the OSA-associated changes in adipose tissue lipolysis might contribute to impaired glucose homeostasis in patient with T2DM. Thirty-five matched subjects were recruited into three groups: T2DM + severe OSA (T2DM + OSA, n = 11), T2DM with mild/no OSA (T2DM, n = 10) and healthy controls (n = 14). Subcutaneous abdominal adipose tissue microdialysis assessed spontaneous, epinephrine- and isoprenaline-stimulated lipolysis. Glucose metabolism was assessed by intravenous glucose tolerance test. Spontaneous lipolysis was higher in the T2DM + OSA compared with the T2DM (60.34 ± 23.40 vs. 42.53 ± 10.16 μmol/L, p = 0.013), as well as epinephrine-stimulated lipolysis (236.84 ± 103.90 vs. 167.39 ± 52.17 µmol/L, p < 0.001). Isoprenaline-stimulated lipolysis was unaffected by the presence of OSA ( p = 0.750). The α 2 anti-lipolytic effect was decreased in T2DM + OSA by 59% and 315% compared with T2DM and controls ( p = 0.045 and p = 0.007, respectively). The severity of OSA (AHI) was positively associated with spontaneous ( p = 0.037) and epinephrine-stimulated ( p = 0.026) lipolysis. The α 2 -adrenergic anti-lipolytic effect ( p = 0.043) decreased with increasing AHI. Spontaneous lipolysis was positively associated with Insulin resistance (r = 0.50, p = 0.002). Epinephrine-stimulated lipolysis was negatively associated with the Disposition index (r = − 0.34, p = 0.048). AHI was positively associated with Insulin resistance ( p = 0.017) and negatively with the Disposition index ( p = 0.038). Severe OSA in patients with T2DM increased adipose tissue lipolysis, probably due to inhibition of the α 2 -adrenergic anti-lipolytic effect. We suggest that dysregulated lipolysis might contribute to OSA-associated impairments in insulin secretion and sensitivity.